Vinko Vinblastin sulfate

Generic Name: Vinblastine Sulfate Injection

Drug Name: Vinblastine

Brand Name: Vinko

Dosage Form: Sterile Lyophilized Powder for Injection

Composition and Description

Active Ingredient: Vinblastine sulfate.

Description: A white or off-white crystalline powder; odorless, hygroscopic, prone to yellowing upon exposure to light or heat, and freely soluble in water.

Specification: 1 mg/mL; 10 mL/vial.

Manufacturer: Kocak Farma

Indications (Requires Combination Chemotherapy Regimen)

Hodgkin Lymphoma (HL) — A core component of the ABVD regimen (+ Doxorubicin + Bleomycin + Dacarbazine).

Non-Hodgkin Lymphoma (NHL).

Advanced Testicular Cancer (in combination with Cisplatin and Bleomycin).

Kaposi's Sarcoma (particularly the AIDS-associated form).

Others: Histiocytosis, Letterer-Siwe disease (off-label use).

Not intended for monotherapy! Combination regimens must be prescribed by a medical oncologist.

Pharmacological Actions

Mechanism of Action: Inhibits tubulin polymerization, thereby preventing the formation of spindle microtubules; this arrests cell division at the metaphase stage and interferes with amino acid transport across the cell membrane as well as protein synthesis.

Pharmacokinetics: Plasma clearance follows a biphasic pattern, with half-lives of 4.5 minutes and 190 minutes, respectively; 33% is excreted via the biliary tract (primarily as metabolites), while 21% is excreted unchanged in the urine.

Dosage and Administration

Intravenous Injection:

Adults: 150 µg/kg of body weight (typically 10 mg). Dilute with 20–30 mL of isotonic saline or 5% glucose solution, then administer via slow intravenous injection or inject into the tubing of a running IV infusion; administer once weekly.

Children: 250 µg/kg of body weight; administration method is the same as for adults.

Course of Treatment: 4–6 weeks, with a total cumulative dose of 60–100 mg.

Intracavitary Injection (Pleural or Abdominal): 10–30 mg per dose. Precautions: The initial dose may be small; subsequent doses should be adjusted based on patient tolerance, but a single dose must not exceed 300 μg/kg of body weight.

Adverse Reactions

Hematologic System: Bone marrow suppression (leukopenia and thrombocytopenia; rapid recovery typically occurs after discontinuation).

Gastrointestinal System: Decreased appetite, nausea, vomiting, and diarrhea (usually mild); abdominal pain and stomatitis are occasionally observed.

Nervous System: Peripheral neuritis (numbness in fingers and toes, limb pain, muscle tremors, loss of deep tendon reflexes); a minority of patients experience headaches or mental depression.

Local Reactions: Thrombophlebitis at the injection site; extravasation may lead to tissue necrosis.

Other: Alopecia (hair loss), orthostatic hypotension, insomnia.

Contraindications

Patients with known hypersensitivity to vinblastine or other vinca alkaloids.

Patients with severe granulocytopenia.

Precautions

Storage: Protect from light; store in a tightly sealed container and refrigerate at temperatures below 10°C.

Special Populations:

Contraindicated in pregnant women (due to teratogenic risks); for breastfeeding women, the potential benefits must be weighed against the risks.

Use with caution in patients with hepatic insufficiency; liver enzymes and bilirubin levels should be monitored.

Drug Interactions:

Itraconazole may increase neurotoxicity (e.g., intestinal obstruction).

Avoid concomitant use with Mitomycin C, Bleomycin, or similar agents (as this may precipitate respiratory or circulatory complications).

Erythromycin may potentiate side effects; the efficacy of anti-epileptic medications may be reduced.

Handling Warning: Intrathecal administration (spinal injection) is strictly prohibited.

Drug Interactions

Exercise caution when co-administering with Cytochrome P450 inhibitors (e.g., Itraconazole), as this may increase plasma drug concentrations.

Avoid concomitant use with hepatotoxic medications to prevent exacerbating the hepatic burden.

Storage Conditions

Store at 2–8°C, protected from light; do not freeze.

Packaging Information

Supplied in 10 mL glass vials, containing 1 mg/mL Vinblastine Sulfate.

Note: Vinblastine Sulfate is a chemotherapeutic agent used to treat various malignant neoplasms. Its critical safety considerations are as follows:

For intravenous use only; intrathecal administration is fatal. The primary toxicity is myelosuppression; therefore, blood counts must be monitored closely.

Administration throughout the entire course of treatment must be conducted under the guidance and close supervision of a medical oncologist.

Product Specifications

Product Name: Vinblastine Sulfate Injection 1 mg/vial (Vinko Vinblastine Sulfate)

Common Name: Vinblastine Sulfate Injection

Composition: Vinblastine Sulfate

Dosage Form: Sterile Lyophilized Powder for Injection

Specification: 1 mg/mL; 10 mL/vial

Manufacturer: Kocak Farma

Indications: Hodgkin Lymphoma (HL) — A core component of the ABVD regimen (+ Doxorubicin + Bleomycin + Dacarbazine)

Non-Hodgkin Lymphoma (NHL)

Advanced Testicular Cancer (in combination with Cisplatin and Bleomycin)

Kaposi's Sarcoma (particularly the AIDS-associated form)

Others: Histiocytosis, Letterer-Siwe Disease (off-label use)

Not intended for use as monotherapy! Combination regimens must be prescribed by a medical oncologist.

Dosage and Administration: Intravenous Injection:

Adults: 150 µg/kg of body weight (typically 10 mg). Dilute in 20–30 mL of isotonic saline or 5% glucose solution, then administer via slow intravenous injection or inject into a running IV infusion line, once weekly.

Children: 250 µg/kg of body weight; administration method is the same as for adults.

Course of Treatment: 4–6 weeks; total cumulative dose: 60–100 mg.

Intracavitary Injection (Pleural/Abdominal): 10–30 mg per dose.

Precautions: The initial dose may be lower and subsequently adjusted based on patient tolerance; however, a single dose must not exceed 300 µg/kg of body weight.